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Objective/background: The objective/background of this work was to study the efficacy and
safety of quercetin and polyvinylpyrrolidone (QP) in the treatment of patients with newly
diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobac-
terial therapy.
Materials and methods: The study involved 124 patients aged between 20 years and 70 years
with newly diagnosed destructive pulmonary tuberculosis. Patients were allocated to two
groups. The first (control) group of patients received standard antimycobacterial and
pathogenetic therapy and included 31 (25.00 ± 3.89%) patients. The second (main) group
of patients received QP therapy in addition to chemotherapy and included 93 (75.00
± 3.89%) patients.
Results: Intoxication symptoms in the second group were reduced following 1.33
± 0.15 months, whereas in the first group intoxication symptoms were reduced following
2.64 ± 0.20 months, p < .001.
Conclusion: Administration of QP combined with chemotherapy in patients with newly
diagnosed destructive pulmonary tuberculosis resulted in a comparatively quick reduction
of disease manifestation.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).kt Nauky,
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 4 4 6 –4 5 3 447Introduction condition but does not reduce immune system impairment.Tuberculosis (TB) is a re-emerging global public health prob-
lem, the incidence of which has increased in the Ukraine, as
well as in other countries [1].
The therapeutic outcome in patients with pulmonary TB
with bacterial excretion remains insufficient despite high effi-
cacy of chemotherapy [2–4]. In 2013, in Ukrainian newly diag-
nosed patients, the frequency of cessation of bacterial
excretion was 63% [5]. Thus, 37% of patients are contagious,
which is favorable for TB circulation in a population [5]. In
addition, the number of patients with primary drug-
resistant Mycobacterium tuberculosis (MTB) has increased
recently not only in Ukraine but all over the world [5–8]. In
patients who excrete MTB, cavitary lesions are usually
observed. It is impossible to achieve complete cure of a
patient because without healing the cavitary lesions which
are the main source of infection, allowing the maintenance
of the microbial population leads to repeated bronchogenic
spread of TB [9,10]. Modern regimens of antimycobacterial
therapy have allowed the cessation of bacterial excretion to
be reached in 67–96% of TB patients [11–13]. Development of
new therapeutic technologies is one of the factors aimed to
increase the treatment efficacy in patients with pulmonary
TB [14]. Combined antibacterial therapy is deemed to be the
main modern method for TB treatment [15,16]. Administra-
tion of antibacterial drugs is essential nowadays.
As defined by the World Health Organization, effective
treatment results in the cessation of bacterial excretion with-
out consideration of destruction healing in the lungs.
Unhealed cavitary lesions are considered as residual changes
[17,18]. However, it was shown [19–21] that unhealed cavitary
lesions may cause TB recurrence under short courses of
chemotherapy associated with no clinical and X-ray signs of
TB improvement. Over the past years, TB recurrence tends
to increase. Thus, the mortality rate related to TB recurrence
increased by sevenfold [22,23].
Thus, the introduction of standard treatment regimens
recommended by the World Health Organization does not
provide a significant increase in the effectiveness of treat-
ment [1].
Gaps in the understanding of the pathophysiologic
networks between the human body and MTB is one of the
reasons for low treatment efficacy. Consequently, combined
therapeutic approaches aim to inhibit MTB and block the
expansion of infected tissues. Thus, we should consider
how to preserve unaffected tissues from further destruction
and prevent any consequences related to TB.
When both myocardial hypoxia, triggered by the destruc-
tion of lung tissue, and TB progress, cardiopulmonary failure
develops and may subsequently lead to the patient’s death.
Restoration of respiratory function in pulmonary TB is an
essential hallmark for clinical cure, and medical and social
rehabilitation of patients with respiratory diseases.
Regulation of the immune system in combined antibacte-
rial therapy was found to be essential for higher efficiency of
administered therapy [24–27]. Intensive antibacterial therapy
reduces intoxication and improves the patient’s generalLung tissue destruction and immune system violations lead
to further progression of inflammation [28,29]. TB outcome
depends on the immunobiological status of the patient, as
well as the complicated symbiotic interaction between MTB
and the human body [30,31].
Every TB type is associated with immunopathological
inflammation caused by the violation of microcirculation
and trophopathy of lung tissue that may be complicated by
matrix destruction, caseous mass excretion through the
bronchi, and destructed region generation. This worsens the
course of TB and may lead to partial or complete lung dys-
function if effective treatment is not administered. It was
demonstrated that a new effective complex treatment in ther-
apeutic conditions is required [28,32,33]. It was shown that
treatment is primarily aimed at MTB elimination. There is
no data available regarding the administration of therapy
leading to lung tissue preservation through limiting patholog-
ical changes and matrix destruction prevention as well as
rapid alleviation of intoxication syndrome associated with
immune system restoration. We investigated the advantages
of quercetin combined with polyvinylpyrrolidone (QP). QP is
a capillary stabilizing agent and antioxidant (bioflavonoids)
with immunomodulatory activity. We have shown that QP
administration in TB-infected mice results in necrosis limita-
tion from spreading to unaffected tissues [34]. Therefore, it
allows localizing necrotic changes, limiting the pathological
process, and preserving the affected lung. The fact that QP
can influence the inflammatory process through necrosis lim-
itation inspired us to investigate QP efficacy in TB patients.
Thus, the aim of our study was to investigate the efficacy
and safety of QP in patients with newly diagnosed destructive
pulmonary TB (NDTB) compared with standard antimycobac-
terial therapy.Materials and methods
Patients
The study involved 124 patients with NDTB who were aged
between 20 years and 70 years. All patients who presented
with NDTB were enrolled in this study.
The patients were allocated to two groups. The first (con-
trol) group of 31 (25.00 ± 3.89%) patients received standard
chemotherapy. The second (main) group of 93 (75.00 ± 3.89%)
patients received QP therapy in addition to standard
chemotherapy.
The first group included 27 (87.10 ± 6.02%) men and four
(12.90 ± 6.02%) women. The second group included 64 (68.82
± 4.80%) men and 29 (31.18 ± 4.80%) women. The difference
between sex and age in both groups was statistically insignif-
icant (p > .05).
All study patients presented with the active form of pul-
monary TB. The most common symptoms were prolonged
heavy cough, pain in the chest, subfebrile temperature fever,
profuse night sweats, fatigue, dyspnea, and loss of weight and
decreased appetite.
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clinical findings compatible with TB, a chest X-ray showing
lung involvement, and a positive sputum smear for acid-fast
bacilli and positive culture for MTB.
On the patients’ admission to hospital, infiltrative TB was
the most common type and was observed in every patient of
the first group. In the second group, infiltrative TB was
observed in 88 (94.62 ± 2.34%) patients. Moreover, five (5.38
± 2.34%) patients of the second group were diagnosed with
disseminated TB. Quantitative characteristics of TB cases
within both groups of patients were evaluated and shown to
be insignificant (p > .05). The difference between the spread
of the TB process in the lungs and the number and size of
destructions was insignificant (p > .05).
Ethics
The project was approved by the Ethics Committee of the
Kharkiv National Medical University, Ukraine. It was con-
ducted according to the Declaration of Helsinki standards.
All of the patients provided written informed consent and
explicitly provided permission for treatment and blood anal-
yses, as well as for the collection of relevant clinical data.
Treatment regimen
All patients received standard chemotherapy, consisting of
orally administered isoniazid (0.3 g), rifampicin (0.6 g), pyrazi-
namide (2 g), ethambutol (1.2 g), and/or an intramuscular injec-
tion of streptomycin (1 g) with a dose reduction after the
intensivephaseof the therapy.Theanti-TBdrugswereprocured
through the Ukraine’s centralized national supply system.
QP was used in a dose of 0.5 g in 100 mL of 0.9% sodium
chloride solution intravenously once per day for 10 days start-
ing on admission to the hospital.
Laboratory evaluation
A standard microbiological examination of a sputum smear
stained using the Ziehl–Neelsen and culture Lo¨wenstein–
Jensen methods was conducted prior to study entry and at
Day 30, Day 90, and Day 150 from the start of treatment.
Isolates of MTB were tested for sensitivity to first- and
second-line anti-TB drugs with a commercially available kit
(Tulip Diagnostics Pvt Ltd., Goa, India). The biochemical
parameters were evaluated using standard routine tech-
niques at baseline and repeated 2 months later.
The levels of cytokines (interleukin [IL]-1b, IL-4, and tumor
necrosis factor-a [TNF-a]) in serumwere evaluated using stan-
dard enzyme-linked immunosorbent assay kits (Vector-Best,
Novosibirsk, Russian Federation). Serum samples for testing
were taken during the 1st days of admission and after
1 month of in-patient treatment. Due to the peculiarities of
the method, we included 20 apparently healthy donors into
the study of cytokines.
X-ray evaluation
Pathological peculiarities, for example, the severity of the
disease and changes in localization, were assessed throughX-ray. Chest fluorography was performed in the out-patient
department for every patient involved in the study. In cases
of pathological findings, we conducted a chest X-ray (two
views). Targeted tomography of the destructed area on
selected sections was performed in every patient.
Interpretation of the thorough X-ray examination allowed
us to estimate newly TB diagnosis, specifically, to detect local-
ization, severity, and peculiarities of TB cavities in the lungs.
X-ray monitoring of patients was repeated every 2 months
following the start of treatment until the end of the continu-
ation phase (8 months).Statistical evaluation
The obtained data were statistically analyzed using standard
Student t test [35]. The difference was considered to be signif-
icant at p < .05.Results and discussion
Regression of intoxication and respiratory symptoms were
the hallmarks of estimating how rapidly disease manifesta-
tion terminates under QP administration. Intoxication symp-
tom regression was evaluated regarding subjective symptoms
(increased appetite, general revival, fatigue, and sweating
alleviation), normalization of body temperature, and body
weight, which were considered as symptoms of TB intoxica-
tion. Respiratory symptoms were evaluated through dyspnea,
cough, and chest pain reduction or alleviation. Data are
shown in Table 1. Therefore, in the second group, patients
demonstrated more rapid intoxication and respiratory symp-
tom alleviation than the first group. Coughing and dyspnea
are mainly related to the severity of the specific process in
the lungs and bronchial lesions. They attenuated more
rapidly in patients of the second group in comparison with
the first group.
Weight gain is a crucial sign of patient’s recovery that may
indicate not only total weight restoration but also the overall
regeneration of affected regions in the human body. Weight
changes following 1 month of treatment in comparison with
weight parameters prior to treatment were as follows: first
group: before treatment 62.35 ± 2.12 kg, 1 month after treat-
ment 64.97 ± 2.03 kg, p = .37; second group: before treatment
64.40 ± 1.07 kg, 1 month after treatment 69.24 ± 1.06 kg,
p = .002. It was found that weight parameters in the second
group were higher in comparison with the first group follow-
ing 1 month of treatment.
Thus, QP treatment resulted in more rapid regression of
intoxication following 1.33 ± 0.15 months in the second group
and following 2.64 ± 0.20 months in the first group (p < .001).
Complete regression of respiratory symptoms in patients of
the second group was observed following 1.43 ± 0.30 months,
and following 2.33 ± 0.30 months in patients of the first group
(p < .05).
Adverse reactions to anti-TB drugs during treatment were
observed in 17 (13.71 ± 3.09%) patients: nine (29.03 ± 8.15%) in
the first group and eight (8.60 ± 2.91%) in the second group
(t = 2.36, p < .05). In the second group, side effects of anti-TB
drugs were observed only at the early phase of treatment.
Table 1 – Period of reduction of tuberculosis clinical signs in patients of the groups.
Clinical symptoms First group Second group p
No. at the beginning
of treatment, (M ± m)
Terms of
disappearance
of clinical
signs (mo), (M ± r)
No. at the beginning
of treatment, (M ± m)
Terms of
disappearance
of clinical signs
(mo), (M ± r)
n % n %
Intoxication symptoms
Weakness 21 67.74 ± 8.40 2.73 ± 1.11 41 44.09 ± 5.15 0.86 ± 0.57 <.05
Loss of appetite 7 22.58 ± 7.51 2.42 ± 0.53 5 5.38 ± 2.34 0.58 ± 0.2 <.05
Fatigue 12 38.71 ± 8.75 3.25 ± 0.45 13 13.98 ± 3.60 2.2 ± 0.44 <.05
Night sweats 17 54.83 ± 8.84 3.23 ± 0.66 24 25.81 ± 4.54 1.28 ± 0.46 <.05
Increased body temperature 19 61.29 ± 8.75 2.05 ± 0.91 21 22.58 ± 4.34 0.55 ± 0.32 <.05
Respiratory symptoms
Cough 26 83.87 ± 6.61 3.38 ± 0.8 44 47.31 ± 5.18 1.84 ± 0.6 <.05
Dyspnea 20 64.52 ± 8.59 1.3 ± 0.41 19 20.43 ± 4.18 0.25 ± 0.15 <.05
Pain in the chest 3 9.68 ± 5.31 2.33 ± 0.32 25 26.88 ± 4.60 1.57 ± 0.53 <.05
Note. The p value is the significance of difference between parameters in Groups 1 and 2. mo = months.
r - mean square deviation value of the indicator; m - arithmetic mean error.
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following two to three injections of QP. Considering these
data, we can assume that QP diminishes adverse reactions
to anti-TB drugs (cardiotoxic disorders, toxic hepatitis, and
allergic dermatitis). Thus, QP provides higher tolerance to
anti-TB drugs by 20.42%. Side effects of QP administration
were not observed. Some patients had more than one side
effect to anti-TB drugs.
A biochemical study through the course of treatment did
not reveal any significant changes of cholesterol, total biliru-
bin, and protein concentrations (thymol test; Table 2). Either
before the start of the therapeutic regimen or following
2 months of treatment these parameters were within normal
limits, except rare cases. Nevertheless, we should also con-
sider alanine aminotransferase and aspartate aminotrans-
ferase concentrations. As shown in Table 2, the toxic effect
on the body in the second group of patients was more promi-
nent compared with the first group prior to the treatment of
TB. Following 2 months of treatment, patients of the first
group demonstrated a significantly higher concentration of
these proteins due to liver and heart-related side effects of
the anti-TB drugs. By contrast, the opposite trend was
observed in patients of the second group, due to the cardio-
protective and hepatoprotective effects of QP in TB and drug
intoxication as we have already shown in mice [34].
In order to elucidate the mechanisms of caseous necrosis
limitation and reduction observed in the experiment [34]
and the immunomodulatory effect of QP, we conducted fur-
ther research aimed at the estimation of cytokine IL-1b,
TNF-a, and IL-4 levels (Table 3).
Prior to treatment, patients of both groups demonstrated a
significant increase in cytokine levels in comparison with
apparently healthy donors (control group in the cytokine
study). Following 1 month of therapy, concentrations of these
cytokines changed significantly. Thus, the levels of IL-1b and
TNF-a significantly decreased. Consequently, a decrease of
TNF-a and IL-1b levels was observed through the course of
standard therapy. QP administration resulted in a more pro-
nounced decrease of TNF-a and IL-1b levels. In contrast tothe reduction of the above-mentioned cytokine levels, IL-4
level increased significantly through the course of treatment.
Standard monthly therapy was associated with an IL-4 level
increase, whereas QP administration resulted in higher IL-4
levels.
Considering the parameters mentioned above, we accen-
tuate a pronounced reduction of IL-1b and TNF-a levels in
the second group of patients compared with the first group.
Reduction of IL-1b and TNF-a due to QP administration
improves the growth of endothelial cells and induces the acti-
vation of microcirculation at the inflammatory site, reduces
blood clotting, and reduces the MTB population. These cytoki-
nes decrease nitric oxide (NO) production in peripheral blood,
as evidenced by the reduction of its metabolites in patients of
the second group. This is supported by the prevention of cell
damage and death, as well as the activation of microcircula-
tion at the inflammatory site where NO increases and elimi-
nates MTB whereas in peripheral blood the NO level
decreases. Moreover, a rapid increase of IL-4 induced by QP
administration reduces the production of reactive oxygen
species by macrophages and indicates an increase of
T-helper population, because these cells predominantly pro-
duce IL-4. Consequently, the caseation process is prevented.
The frequency of bacterial excretion cessation is a crucial
parameter used to evaluate the efficacy of pulmonary NDTB
treatment (Tables 4 and 5). The obtained data demonstrate
that bacterial excretion cessation is observed following a sig-
nificantly shorter period of treatment in the second group
compared with the first group that was confirmed with both
microscopic study and culture.
Furthermore, healing of cavitary lesions and the elimina-
tion of infiltrative changes is one of the most important indi-
cators in evaluating the efficacy of pulmonary NDTB
treatment (Table 6). Throughout the period of observation,
the healing of cavities was more common in patients of the
second group.
Both groups showed similar results for the duration period
when infiltrative changes decline (Table 6) and cavitary
lesions completely close up. The only exceptions were a few
Table 3 – Levels of interleukin (IL)-1b, IL-4, and tumor necrosis factor-a (TNF-a) in tuberculosis patients compared with apparently healthy donors.
Groups of patients n IL-1b (pg/L) TNF-a (pg/L) IL-4 (pg/L)
Before treatment After 1 mo of treatment Before treatment After 1 mo of treatment Before treatment After 1 mo of treatment
1 30 166.8 ± 5.2* 78.07 ± 3.1** 185.4 ± 5.57* 125 ± 5.84** 62.63 ± 2.61* 85.19 ± 3.01**
2 89 168.7 ± 5.02* 67.92 ± 2.1** 202 ± 4.72* 127.4 ± 4.63** 57.51 ± 1.56* 97.46 ± 3.02**
Relatively healthy 20 55.91 ± 5.21 34.73 ± 3.68 30.75 ± 1.13
Note. mo = month.
* Difference is significant (p < .001) in comparison with apparently healthy donors.
** Difference is significant (p < .001) in comparison with group prior to treatment and following 1 month of treatment.
Table 2 – Dynamics of the main biochemical parameters in observed patients (M ± r).
Biochemical parameters Thymol test, (un SH) Total bilirubin (lmol/L) ALT (lmol/L) AST (lmol/L) Total
protein (g/L)
Cholesterol
(mmol/L)
Group 1 No. on admission n 31 31 3a 28 9a 22 31 31
% 100 100 9.7a 90.3 29a 71 100 100
On admission to hospital 1.63 ± 0.91 9.8 ± 1.26 1.26 ± 0.51a 0.3 ± 0.15 0.82 ± 0.39a 0.26 ± 0.12 78.76 ± 9.23 4.51 ± 0.92
No. in 2 mo of treatment n 31 31 11a 20 17a 14 31 31
% 100 100 35.4a 64.6 54.8a 45.2 100 100
In 2 mo of treatment 2.21 ± 1.21 10.24 ± 1.91 1.14 ± 0.57a 0.26 ± 0.13 0.84 ± 0.38a 0.26 ± 0.17 79.92 ± 8.63 4.69 ± 1.04
Group 2 No. on admission n 93 93 16a 77 42a 51 93 93
% 100 100 17a 83 45a 55 100 100
On admission to hospital 1.95 ± 0.97 9.93 ± 1.4 1.93 ± 1.4a 0.36 ± 0.17 1.07 ± 0.89a 0.23 ± 0.097 80.04 ± 7.72 4.39 ± 0.92
No. in 2 mo of treatment n 93 93 6a 87 11a 82 93 93
% 100 100 6a 94 12a 88 100 100
In 2 mo of treatment 1.62 ± 0.88 9.53 ± 1.23 1.16 ± 0.63a 0.24 ± 0.15 0.96 ± 0.5a 0.26 ± 0.11 80.96 ± 7.63 4.66 ± 0.91
p >.05 >.05 >.05a >.05 >.05a >.05 >.05 >.05 >.05
p in mo of treatment >.05 >.05 >.05a >.05 >.05a >.05 >.05 >.05 >.05
Note. The p value is the significance of difference between parameters in Groups 1 and 2.
r - mean square deviation value of the indicator; un SH - Shank-Hoagland units, unit of measurement of this indicator.
ALT = alanine transaminase; AST = aspartate transaminase; mo = months.
a The parameters increased above normal.
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Table 4 – Indicators of bacterial excretion cessation as evidenced by microscopic examination of sputum and bronchial
washing.
Stages of treatment (mo)a Group 1 Group 2
n % n %
On admission to hospital 27 87.10 ± 6.02 86 92.47 ± 2.74
1 15 55.56 ± 9.75 76 88.37 ± 3.46*
3 5 18.52 ± 7.62 8 9.30 ± 3.13
5 7 25.93 ± 8.59 2 2.33 ± 1.63*
Note. mo = months.
a Index value at each stage is calculated based on previous values.
* Difference is significant (p < .05) in comparison with Group 1.
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healing, or when cavities were healed prior to a complete
reduction of infiltration.
Thus, the second group of patients demonstrated a consid-
erably shorter period of cavitary lesion healing than the first
group.
Treatment efficacy should be evaluated considering not
only the immediate human body response to treatment but
also residual changes following the completion of the main
course of antimycobacterial therapy in both groups.
Slight residual changes were observed following the
administration of anti-TB drugs in combination with QP
in patients with pulmonary NDTB. Slight residual changes
at the site of healed cavities, or even no signs were found
in 84 (90.32 ± 3.07%) patients of the second group com-
pared with 22 patients (70.97 ± 8.15%) in the first group
(t = 2.22, p < .05). Pronounced residual changes were found
in nine (9.68 ± 3.07%) patients of the second group and
in nine (29.03 ± 8.15%) patients of the first group (t = 2.22,
p < .05).Table 5 – Indicators of bacterial excretion cessation as evidence
washing.
Stages of treatment (mo)a Group 1
n %
On admission to hospital 29 9
3 21 7
5 8 2
Note. mo = months.
a Index value at each stage is calculated based on previous values.
* Difference is significant (p < .05) in comparison with Group 1.
Table 6 – Indicators of cavitary lesion healing and infiltrative ch
Stages of treatment (mo)a Group 1
n %
2 10 3
4 15 4
6 20 6
Total: 8 26 8
Note. mo = months.
a Index value at each stage is calculated based on previous values.
* Difference is significant (p < .05) in comparison with Group 1.It should be noted that QP administration affects the inci-
dence of residual changes following a completed course of
antimycobacterial therapy and reduces the number of pro-
nounced residual changes by increasing the frequency of
slight residual changes. We deem that these changes
occurred due to the hepatoprotective and immunomodula-
tory properties of QP.
It should be accentuated that the treatment of pulmonary
NDTB by the application of QP in combination with antimy-
cobacterial therapy accelerates the normalization of the clin-
ical manifestation of TB, and reduces the incidence of adverse
reactions to antimycobacterial drugs and the progress of the
specific process. The drug caused no adverse effects in
observed patients. The drug reduces the period of cessation
of bacterial excretion, increases the frequency of healing of
cavities and frequency of complete clinical and radiological
cure, and decreases the number of pronounced residual
changes after treatment.
This pathogenic effect of treatment will further improve
the patient’s life after curing TB, prevent TB recurrence, andd by bacteriologic examination of sputum and bronchial
Group 2
n %
3.55 ± 4.41 86 92.47 ± 2.74
2.41 ± 8.45 84 97.67 ± 1.63*
7.59 ± 8.45 2 2.33 ± 1.63*
ange alleviation in pulmonary tissue.
Group 2
n %
2.26 ± 8.40 58 62.37 ± 5.02*
8.39 ± 8.98 3 78.49 ± 4.26*
4.52 ± 8.59 82 88.17 ± 3.35*
3.87 ± 6.61 91 97.85 ± 1.50*
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of TB treatment in the future.
Conclusion
Administration of QP combined with chemotherapy in
patients with NDTB resulted in a comparatively quick reduc-
tion of disease manifestation. Specifically, intoxication symp-
toms in the second group were reduced following 1.33
± 0.15 months, whereas following 2.64 ± 0.20 months in the
first group, p < .001. Moreover, respiratory symptoms regres-
sion in the second group was observed following 1.43
± 0.30 months, whereas following 2.33 ± 0.30 months in the
first group, p < .05. The bacillary excretion period evaluated
within 3 months was reduced by 97.67 ± 1.63% in the main
group compared with 72.41 ± 8.45%, p < .05, in the control
group. In addition, the period of destructed cavity healing
was reduced to 2.86 ± 0.15 months in the main group com-
pared with 3.43 ± 0.20 months, p < .05, in the control group.
Residual abnormal X-ray findings (mild or slight or even no
signs) were observed in 84 (90.32 ± 3.07%) patients of the main
group versus 22 (70.97 ± 8.15%) patients in the control group.
Significant residual findings were observed in nine (9.68
± 3.07%) patients of the main group and in nine (29.03
± 8.15%) patients of the control group, p < .05.
QP in patients with NDTB does not cause side effects.
Furthermore, QP provides a higher tolerance to anti-TB drugs
by 20.42%.
QP administration in patients with pulmonary TB can
increase the concentration of IL-4 and reduce the levels of
IL-1b and TNF-a in serum which is evidence of the
immunotherapeutic effect of QP.
Indications for QP administration with antimycobacterial
therapy in patients with NDPB include side effects of antimy-
cobacterial drugs, reduced immunological reactivity, severity
of the case, and TB intoxication.
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